Takeda Pharmaceutical Co Ltd (NYSE: TKPHF)

Takeda Pharmaceutical Company Limited, commonly known as Takeda, is a global biopharmaceutical firm specializing in research, development, manufacturing, and marketing of pharmaceutical products. The company operates in five primary business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience. Takeda's main products include ENTYVIO, ALOFISEL, EOHILIA, TAKHZYRO, LIVTENCITY, ADZYNMA, Immunoglobulin products, Albumin products, ALUNBRIG, EXKIVITY, FRUZAQLA, and QDENGA.

Takeda's Gastroenterology segment concentrates on developing and commercializing treatments for gastrointestinal and inflammatory bowel diseases. ENTYVIO, a treatment for moderate to severe ulcerative colitis and Crohn's disease, is one of the company's top-selling products, generating JPY 800.9 billion in sales in the fiscal year ending March 31, 2024. ALOFISEL, a treatment for complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn's disease, was approved in Europe in 2018 and in Japan in 2021. EOHILIA, a therapy for eosinophilic esophagitis (EoE), was approved by the U.S. FDA in February 2024 and launched in the fiscal year ending March 31, 2024.

The Rare Diseases segment focuses on developing and commercializing treatments for rare and orphan diseases. TAKHZYRO, a treatment for hereditary angioedema (HAE) attacks, was approved for patients 12 years of age and older in both the U.S. and Europe in 2018, and in Japan in 2022. LIVTENCITY, a treatment for post-transplant cytomegalovirus (CMV) infection/disease, was launched in the U.S. in December 2021 and approved in Europe in November 2022 and China in December 2023.

Takeda's Plasma-Derived Therapies segment focuses on the development and commercialization of plasma-derived products, including Immunoglobulin and Albumin products. The segment includes products such as GAMMAGARD LIQUID/KIOVIG, HYQVIA, and CUVITRU.

In the Oncology segment, Takeda develops and commercializes treatments for various types of cancer, including ALUNBRIG, EXKIVITY, and FRUZAQLA. The Neuroscience segment focuses on the development and commercialization of treatments for neurological disorders, including QDENGA, a dengue vaccine.

Takeda is a global company with operations in approximately 80 countries and regions, employing around 49,000 people worldwide dedicated to improving people's health and creating a brighter future through innovative medicine. In terms of its competitive position, Takeda is a leading player in the biopharmaceutical industry, with a diverse portfolio of products and a strong pipeline of innovative medicines. The company has a strong presence in the Gastroenterology and Rare Diseases segments and is also a major player in the Oncology and Neuroscience segments. Takeda's competitive advantages include its robust research and development capabilities, global commercialization network, and commitment to patient-focused innovation.

Takeda's customers include patients, healthcare providers, and payers, and its products are marketed and sold through a network of distributors and wholesalers and its own sales force. The company also partners with other companies to develop and commercialize new products, with a strong track record of successful partnerships.

Takeda's R&D engine is focused on areas of high unmet medical needs, both in rare and more prevalent conditions, across three core therapeutic areas: gastrointestinal and inflammation, neuroscience, and oncology. The company's pipeline includes a range of products in development, including small molecules, biologics, and cell and gene therapies.